A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies

Clin J Gastroenterol. 2015 Apr;8(2):88-91. doi: 10.1007/s12328-015-0558-y. Epub 2015 Mar 21.

Abstract

There are few reports about the rapid appearance of anti-adalimumab antibodies in patients with Crohn's disease positive for anti-infliximab antibodies. We report the case of a 29-year-old female patient with a diagnosis of Crohn's disease who revealed a loss of response to infliximab due to high levels of antibodies to infliximab, and did not respond to the subsequent therapy by adalimumab, with a rapid appearance of antibodies to adalimumab. As one of the possible mechanisms of non-response to adalimumab, immunologic reactivity of infliximab to adalimumab was suspected, since the patient's IgG that was obtained just before the induction of adalimumab reacted with infliximab and adalimumab. We should pay attention to the easy appearance of anti-adalimumab antibodies in association with reactivity of anti-infliximab antibodies to adalimumab in patients with high levels of anti-infliximab antibodies.

Publication types

  • Case Reports
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / immunology*
  • Adalimumab / therapeutic use
  • Adult
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology*
  • Female
  • Gastrointestinal Agents / immunology*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Immunoglobulin G / blood*
  • Infliximab / immunology*
  • Infliximab / therapeutic use

Substances

  • Gastrointestinal Agents
  • Immunoglobulin G
  • Infliximab
  • Adalimumab